Skip to main content
  • Book
  • © 2015

Optimization of Pharmaceutical R&D Programs and Portfolios

Design and Investment Strategy

  • Addresses the impact of study design on maximizing the output at the portfolio level in the pharmaceutical industry

  • Examines portfolio optimization comprehensively by integrating input from multiple stakeholders

  • Provides an integrated approach that considers value proposition earlier in the clinical development process by incorporating marketing, commercial and medical affairs perspectives

  • Includes supplementary material: sn.pub/extras

Buying options

eBook USD 169.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-09075-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 219.99
Price excludes VAT (USA)
Hardcover Book USD 219.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (12 chapters)

  1. Front Matter

    Pages i-viii
  2. Background

    1. Front Matter

      Pages 17-17
    2. Clinical Aspects of Pharmaceutical Portfolio Management

      • Frederic (Rick) Sax, Raymond A. Huml, Judith Ng-Cashin
      Pages 19-33
    3. Drug Development and the Cost of Capital

      • Kraig F. Schulz, Sarah T. Bobulsky, Frank S. David, Nitin R. Patel, Zoran Antonijevic
      Pages 35-47
  3. Quantitative Methodology

    1. Front Matter

      Pages 81-81
    2. Impact of Phase 2b Strategies on Optimization of Drug Development Programs

      • Zoran Antonijevic, Jim Bolognese, Carl-Fredrik Burman, Christy Chuang-Stein, Chris Jennison, Martin Kimber et al.
      Pages 83-103
    3. Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications

      • Jack Kloeber Jr., Alex Stojanovic, C. Kwon Kim
      Pages 123-139
    4. Maximizing Return on Investment in Phase II Proof-of-Concept Trials

      • Cong Chen, Robert A. Beckman, Linda Z. Sun
      Pages 141-154
    5. Portfolio Optimization of Therapies and Their Predictive Biomarkers

      • Robert A. Beckman, Cong Chen
      Pages 155-180
  4. Erratum

    • Zoran Antonijevic
    Pages E1-E1
  5. Back Matter

    Pages 201-202

About this book

Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio’s value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria.    

This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians.

Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader. 

Keywords

  • Decision Analysis
  • Decision Making
  • Optimization
  • Pharmaceutical Portfolio
  • Portfolio Optimization
  • Quantitative Methods

Editors and Affiliations

  • Cytel Inc., Cambridge, USA

    Zoran Antonijevic

About the editor

Zoran Antonijevic is a Senior Director at Cytel Consulting with responsibility for strategic advice at trial, program, or portfolio level.  His research areas include: adaptive design, pharmaceutical portfolio optimization, and decision-making within clinical drug development process. Zoran has 20 years of experience in drug development. His prior experience includes positions at Harvard School of Public Health, GlaxoSmithKline, and Quintiles Innovation where his primary responsibility was to develop designs and approaches that maximize probability of success for programs and/or maximize product's value. He also has extensive experience with performing due-diligence, and as a member of product portfolio executive teams. Externally, Zoran is the chair of DIA Adaptive Design Scientific Working Group.

Bibliographic Information

  • Book Title: Optimization of Pharmaceutical R&D Programs and Portfolios

  • Book Subtitle: Design and Investment Strategy

  • Editors: Zoran Antonijevic

  • DOI: https://doi.org/10.1007/978-3-319-09075-7

  • Publisher: Springer Cham

  • eBook Packages: Business and Economics, Business and Management (R0)

  • Copyright Information: Springer International Publishing Switzerland 2015

  • Hardcover ISBN: 978-3-319-09074-0

  • Softcover ISBN: 978-3-319-34312-9

  • eBook ISBN: 978-3-319-09075-7

  • Edition Number: 1

  • Number of Pages: VIII, 202

  • Number of Illustrations: 14 b/w illustrations, 24 illustrations in colour

  • Topics: Operations Research and Decision Theory, Optimization, Biostatistics

Buying options

eBook USD 169.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-09075-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 219.99
Price excludes VAT (USA)
Hardcover Book USD 219.99
Price excludes VAT (USA)